Sequential treatment strategy in dyslipidemia vs earlier use of combination therapies: decision-making factors Dyslipidemia 28 Aug 2021 Sequential treatment strategy in dyslipidemia vs earlier use of combination therapies: decision-making factors Join the ESC 2021 Satellite Symposium sponsored by Servier on factors important for decision-making in dyslipidemia with Alberto Zambon, Evangelos Liberopoulos and Francois Schiele.
From pathophysiology to clinical benefits: what new combinations of a statin and antihypertensive drugs can provide Hypertension Symposia & Webinars From pathophysiology to clinical benefits: what new combinations of a statin and antihypertensive drugs can provide Professor Claudio Borghi analyses statins, ACEi and CCB treatment strategy for patients with hypertension and hypercholesterolemia.
Q&A session: Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy Dyslipidemia Symposia & Webinars Q&A session: Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy An open discussion with A. Zambon and L. Perez de Isla on questions submitted by the audience at ESC 2020.
Broader usage of combinations in daily clinical practice: what benefits for patients? Dyslipidemia Symposia & Webinars Broader usage of combinations in daily clinical practice: what benefits for patients? Alberto Zambon discusses in detail the use of combinations therapies to manage LDL-C.
